Case report

**Scedosporium apiospermum** fungemia successfully treated with voriconazole and terbinafine

Ra'ed Jabr\(^a\), Kassem Hammoud\(^b,\)*

\(^a\) Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA
\(^b\) Division of Infectious Diseases, University of Kansas Medical Center, Kansas City, KS 66160, USA

---

**ARTICLE INFO**

**Article history:**
Received 15 July 2020
Received in revised form 5 August 2020
Accepted 6 August 2020

**Keywords:**
Scedosporium apiospermum
Fungemia

---

**ABSTRACT**

*Scedosporium apiospermum* is ubiquitous in the environment and is considered an emerging infection. Immunocompromised hosts can have a wide spectrum of diseases ranging from cutaneous to disseminated disease that may involve pulmonary, central nervous system, or bone. Disseminated disease in immunocompetent hosts is uncommon. Treatment of deep-seated infections is challenging because of the limited susceptibility of the *Scedosporium* species to all current antifungal drugs. We report a case of *Scedosporium apiospermum* fungemia with a presumed pulmonary involvement in an immunocompetent patient. The fungemia was successfully treated with oral voriconazole and terbinafine.

© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

---

**Introduction**

*Scedosporium apiospermum* (*S. apiospermum*) is an environmental pathogen that can be found in soil, sewage, and polluted water [1]. Infections caused by this organism occur in the paranasal sinuses, lungs, skin, soft tissue, central nervous system, and bones. Disseminated disease is also common with usually hematogenous dissemination [1]. It is an emerging pathogen associated with the increase use of glucocorticosteroids, immunosuppressive therapy, and chemotherapy [2]. *S. apiospermum* is considered as a major cause of non-Aspergillus mold infections in organ transplant recipients and cystic fibrosis patients [3]. It is important to have an accurate and prompt diagnosis because *S. apiospermum* can be misidentified as other molds with different resistance profiles, such as *Aspergillus* species (spp).

**Case report**

A 72-year-old female patient was admitted to the hospital with fever, intermittent hemoptysis, and worsening shortness of breath of 2–3 weeks duration. Her past medical history is significant for severe primary pulmonary arterial hypertension on treprostinil infusion through a peripherally inserted central catheter (PICC). Physical examination was remarkable for temperature of 102 F, crackles on lungs examination, and tunneled right internal jugular catheter with no local signs of infection. Initial work up showed white blood cell count of 12,500/ul with normal differential. Her respiratory viral panel from nasal wash, urine legionella antigen, and Streptococcus urinary antigen were negative. Computer tomography (CT) of the chest showed scattered ill-defined airspace opacities in both lungs (Fig. 1). She was started on broad spectrum antibiotics for suspected community acquired pneumonia. On hospital day two, she was transferred to the ICU after an episode of massive hemoptysis and acute hypoxemic respiratory failure. Bronchoscopy showed normal appearance of the trachea and bronchial tree. Her automated blood cultures obtained on admission grew *S. apiospermum* (after 5 days of incubation). The patient was started on voriconazole and liposomal amphotericin B. The source of fungemia was thought to be secondary to PICC infection, and it was removed. The tip of the PICC and bronchoalveolar lavage fungal cultures remained negative. Her Aspergillus Galactomannan antigen index was 0.109 (reference value < 0.5) and HIV serology was negative. A repeat CT scan of the chest on day 14 after initiation of antifungal therapy showed worsening diffuse lung nodules (Fig. 2). She was clinically stable but remained hypoxic, her (1,3)-Beta-D-Glucan (Fungitell) decreased from 257 pg./ml to 164 pg./ml (normal < 60 pg./ml). Susceptibility testing is summarized in Table 1, terbinafine susceptibility and antifungal synergy testing were not performed. Micafungin was added later during the hospital course. The patient expressed wishes to be transitioned to oral antifungals and to

---

\* Corresponding author at: Department of Internal Medicine, Division of Infectious Diseases, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.
E-mail addresses: rjabr@kumc.edu (R. Jabr), khammadou@kumc.edu (K. Hammoud).

https://doi.org/10.1016/j.idcr.2020.e00928

2214-2509/© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
**Discussion**

_Scedosporium/Lomentospora_ spp is a major cause of infection in immunocompromised patients. It has been recognized that _Scedosporium_ spp. can also cause severe infection in immunocompetent hosts (in victims of near-drowning or after penetrating trauma). _Scedosporium_ spp. was identified as the second most common filamentous fungi after _Aspergillus_ spp. in a study done in Spain [4]. It causes broad spectrum of diseases, including skin and soft tissue infections, septic arthritis, osteomyelitis, sinusitis, pneumonia, meningitis, brain abscesses, endocarditis, keratitis, chorioretinitis, endophthalmitis, and disseminated infection.

_S. apiospermum_ was initially considered the anamorph of _Scedosporium boydii_ (formerly known as _Pseudallescheria boydii_). In 2005, it was found that they are two distinct species based on molecular, physiological, and biochemical data [5]. _S. apiospermum_ complex has been recognized to encompass five distinct species: _S. apiospermum, S. auranticum, S. boydii, S. minutissimum_, and _S. dehoogii_ [6]. Out of these five species, _S. apiospermum, S. auranticum_ and _S. boydii_, are causing human infections [6].

_Lomentospora prolificans_ (formerly _Scedosporium prolificans_) was named as _Scedosporium inflatum_ when first isolated due to its basally swollen, flask-shaped cells but was later named _S. prolificans_ [7]. Based on ultrastructure and DNA-DNA hybridization analysis, this organism was subsequently assigned to the genus _Lomentospora_ and reclassified as _Lomentospora prolificans_ [8]. There is no available active antifungal therapy for _Lomentospora prolificans_.

One case series and review of literature of _S. apiospermum_ and _L. prolificans_ infections in transplant recipients revealed 80 cases, the majority were _S. apiospermum_ (58 patients) [10]. Fungemia reported in 40 % (4/10) of organ transplant recipients with _L. prolificans_, compared with 4.7 % (2/43) of those with _S. apiospermum_ infections [9]. Another review of the literature showed that 12 out of 204 cases had fungemia (5.8 %) (compared to 46.4 % in _L. prolificans_). Among the 12 patients with _S. apiospermum_ fungemia, seven were immunosuppressed (six of them are solid organ transplant recipients), five were immunocompetent [10]. All 12 patients with fungemia died and death was mostly attributed to the infection with overall attributable mortality of 76 %. In this case series, the authors performed an electronic literature search for case reports in PubMed and the FungiScope registry.

Voriconazole is the antifungal agent of choice for treatment of _S. apiospermum_ given efficacy and good tolerance [11]. In _vitro_ data suggest that micafungin is the second most active antifungal agent against _S. apiospermum_ [12]. The combination of micafungin and voriconazole in _vitro_ has been demonstrated to have a synergistic effect against several fungi including _Scedosporium spp_ [13]. Studies have shown that terbinafine monotherapy has poor potency against _Scedosporium_ species (MIC90, >16 µg/mL) but the addition of terbinafine to voriconazole has a potential synergistic role based on case reports [14–17]. Henao-Martinez et al. reported two cases of _S. apiospermum_ CNS infections treated successfully with the combination of voriconazole and terbinafine [14]. Musk et al. reported two cases of successful treatment of post-lung transplant _S. apiospermum_ infection with same combination therapy [15]. Rolfe et al. reported a case of _S. apiospermum_ pulmonary infections in a cystic fibrosis that was treated with voriconazole and terbinafine prior to lung transplantation two months after starting the therapy [16]. Following lung transplant, multiple bronchoscopes were performed and remained negative for the growth of bacterial or fungal organisms. Voriconazole was discontinued after six months; and terbinafine discontinued after nine months (from transplant). Goldman et al. reported a 77-year-old man on high dose steroids for presumed temporal arteritis who has cutaneous _S. apiospermum_ infection that disseminated on consider hospice care if any further deterioration. She was discharged on oral voriconazole and terbinafine. Repeat blood cultures were negative. She had a gradual resolution of her symptoms. A CT scan of the chest, done 12 days after discharge (2 weeks after changing antifungal therapy to voriconazole and terbinafine), showed significant improvement, and a repeat CT scan 6 months after discharge showed almost resolution of pulmonary infiltrates and nodules. The patient was treated for a total of 7 months with voriconazole and terbinafine with no evidence of relapse after 7 years of follow up.

| Antifungal Agent | MIC (mcg/mL) |
|------------------|--------------|
| Itraconazole     | 2            |
| Voriconazole     | 1            |
| Posaconazole     | 1            |
| Amphotericin B   | > 8          |
| Micafungin       | 0.25         |
| Caspofungin      | > 8          |

MIC: minimal inhibitory concentration. Testing performed at University of Texas Health Science Center according to CLSI M38-A2 (both dilution). There are no established breakpoints for _S. apiospermum_ antifungal susceptibility.

Fig. 1. Computed tomography of the chest on admission showing scattered ill-defined airspace opacities in both lungs.

Fig. 2. Repeat CT scan of the chest 14 days after starting voriconazole and liposomal amphotericin B showing worsening lungs findings with innumerable nodules.

Table 1

Antifungal Susceptibility testing for _Scedosporidium apiospermum_.

| Antifungal Agent | MIC (mcg/mL) |
|------------------|--------------|
| Itraconazole     | 2            |
| Voriconazole     | 1            |
| Posaconazole     | 1            |
| Amphotericin B   | > 8          |
| Micafungin       | 0.25         |
| Caspofungin      | > 8          |

MIC: minimal inhibitory concentration. Testing performed at University of Texas Health Science Center according to CLSI M38-A2 (both dilution). There are no established breakpoints for _S. apiospermum_ antifungal susceptibility.
voriconazole [17]. The addition of micafungin and granulocyte
macrophage colony-stimulating factor (GM-CSF) provided partial recovery.

Our patient didn’t have evidence of immunosuppression, we
believe this is the first reported case of fungus associated with
with central line infection with secondary pulmonary dissemi-
nation. This case also adds to the anecdotal evidence that the combination therapy with voriconazole and terbinafine may be
synergistic and effective for the treatment of S. apiospermum invasive infection.

Declaración de Competing Interest

The authors report no declarations of interest.

References

[1] Shinohara Michi M, George Evan. Scedosporium apiospermum: an emerging opportunistic pathogen that must be distinguished from Aspergillus and other hyalohyphomycetes. J Cutan Pathol 2009;36:39–41.

[2] Uenotisuchi Takeshi, Moroi Yoichi, Urabe Kazunori, Tsuji Gaku, Kogas Tetsuya, Matsuda Tetsuo, et al. Cutaneous Scedosporium apiospermum infection in an immunoocompromised patient and a review of the literature. Acta Derm Venereol 2005;85(2).

[3] Husain Shahid, Alexander Barbara D, Munoz Patricia, Avery Robin K, Houston Sally, Pruett Timothy, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003;37(2):221–9.

[4] Ablaouwy-Izzaouda A, Mellado Emilia, Peláez T, Penán J, Zapico S, Alvarez M, et al. Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). Antimicrob Agents Chemother 2013;57(7):3380–7.

[5] Gildado Felix, Cano Josep, Gene Josepa, Guarro Josep. Molecular phylogeny of the Pseudallescheria boydii species complex: proposal of two new species. J Clin Microbiol 2005;43(10):4930–42.

[6] Tóth Eszter J, Nagy Géza R, Homa Mónika, Ábrók Marianna, Kiss Ildikó É, Nagy Gábor, et al. Recurrent Scedosporium apiospermum mycetoma successfully treated by surgical excision and terbinafine treatment: a case report and review of the literature. Ann Clin Microbiol Antimicrob 2017;16(1):31.

[7] Malloch D, Salkin IF. A new species of Scedosporium associated with osteomyelitis in humans. Mycologia 1984;21(10–11):247–55.

[8] Guého E, Sylver De Hoog G. Taxonomy of the medical species of Pseudallescheria and Scedosporium. Journal de Mycologie Médicale 1991;1(1):3–9.

[9] Husain Shahid, Muñoz Patricia, Forrest Graeme, Alexander Barbara D, Somani Jyoti, Brennan Kathleen, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005;40(1):89–99.

[10] Seedel Daniela, Mevissen Arne, Lackner Michaela, Piepenbrock Ellen, Salmantont-Garcia Jon, Stecher Melanie, et al. Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope®. Crit Rev Microbiol 2019;45(1):1–21.

[11] Troke Peter, Aguirebengoa Koldo, Atroaga Carmen, Ellis David, Heath Christopher H, Lutsar Irja, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008;52(5):1743–50.

[12] Lackner Michaela, Sylven De Hoog G, Verweij Paul E, Najafzadeh Mohammad J, Curfs-Breuker Ilse, Klaassen CornéH, et al. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother 2012;56(9):2635–42.

[13] Heyn Kathrin, Tredup Antje, Salvenmoser Stefanie, Müller Frank-Michael C. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. And Fusarium solani. Antimicrob Agents Chemother 2005;49(12):5157–9.

[14] Henao-Martinez Andrés F, Castillo-Mancilla JoséR, Barron Michelle A, Nichol Aran Cunningham. Combination antifungal therapy in the treatment of Scedosporium apiospermum central nervous system infections. Case Rep Infect Dis 2013;2013.

[15] Musk Michael, Chambers Daniel, Chin Weng, Murray Ronan, Gabbay Eli. Successful treatment of disseminated Scedosporium infection in 2 lung transplant recipients: review of the literature and recommendations for management. J Heart Lung Transplant 2006;25(10):1268–72.

[16] Rolfe Nancy E, Haddad Tarik J, Wills Todd S. Management of Scedosporium apiospermum in a pre-and post-lung transplant patient with cystic fibrosis. Med Mycol Case Rep 2013;2:37–9.

[17] Goldman Chlee, Akiyama Matthew J, Torres Julian, Louie Eddie, Meehan Shane A. Scedosporium apiospermum infections and the role of combination antifungal therapy and GM-CSF: a case report and review of the literature. Med Mycol Case Rep 2016;11:40–3.